Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06593522 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
A Phase 2 study of MTAP-deleted NSCLC, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06593522 is a Phase 2 study of MTAP-deleted NSCLC that is actively recruiting participants, run by Amgen. The registered enrollment target is 200 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT06593522, a Phase 2 study of MTAP-deleted NSCLC, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
Conditions Studied
Interventions
- DRUG AMG 193
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Duarte
- Cedars-Sinai Medical Center - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- University of California Los Angeles - Los Angeles
Texas
- Texas Oncology Central/South Texas - Austin
- Sarah Cannon Research Institute - Dallas
- Texas Oncology - Dallas Fort Worth - Dallas
- US Oncology Research Investigational Products Center - Irving
- Texas Oncology Northeast Texas - Tyler
Connecticut
- Eastern Connecticut Hematology and Oncology Associates - Norwich
- Hartford HealthCare Cancer Institute - Manchester - Plainville
Michigan
- Trinity Health Saint Joseph Mercy Ann Arbor - Ann Arbor
- Cancer and Hematology Centers of Western Michigan - Grand Rapids
Tennessee
- Sarah Cannon Research Institute Oncology Partners - Nashville
- United States Oncology Regulatory Affairs Corporate Office - Nashville
Colorado
- Rocky Mountain Cancer Centers - Denver
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Louisiana
- Our Lady of the Lake Cancer Institute - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-12-26 |
| Est. Completion | 2030-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06593522
The ClinicalTrials.gov registry entry for NCT06593522 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with MTAP-deleted NSCLC appearing as the primary indexed condition, and to 1 intervention - of which AMG 193 is the first listed.
NCT06593522 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06593522 about?
NCT06593522 is a clinical study titled "A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)". The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
What is the current status of trial NCT06593522?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-12-26. Estimated completion is 2030-11-29.
What conditions does trial NCT06593522 study?
This clinical trial studies the following conditions: MTAP-deleted NSCLC.
What interventions are being tested in trial NCT06593522?
The interventions under investigation include: AMG 193 (DRUG).
Who is sponsoring clinical trial NCT06593522?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06593522 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.